Novartis (NVS) announced it “is pleased with the decision by the US Court of Appeals for the Federal Circuit, CAFC, that affirms the validity of the Entresto combination patent. We will work to appropriately enforce the combination patent through its pediatric exclusivity period expiring in July 2025. We will also continue to defend and protect all our important intellectual property and regulatory rights relating to Entresto.” There are currently no generic versions of Entresto available in the US.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVS:
- Illumina launches pilot proteomics program with UK Biobank, collaborators
- Biogen appoints Feire as Head of Business Development and External Innovation
- Novartis’ Gene Therapy Shows Promise in Treating SMA
- Novartis reports Phase 3 STEER study met primary endpoint
- Hunterbrook Capital long Bioage Labs, Hunterbrook Media reports